LBA-4 Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703

Results from the phase III BMT CTN 1703 trial compared outcomes in alloHCT patients who were randomized to receive post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil (PTCy/Tac/MMF) versus standard of care plus methotrexate (Tac/MTX). It found that there was a higher one-year GVHD-free, relapse-free survival with PTCy/Tac/MMF than with Tac/MTX.